Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2019
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Steven B Maron, Leah M Chase, Samantha Lomnicki, et al.
Cancer Discovery
|
February 17, 2018
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i>-Amplified Gastroesophageal Adenocarcinoma
Steven B Maron, Lindsay Alpert, Heewon A Kwak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
David S Hong, Patricia LoRusso, Omid Hamid, et al.
Therapeutic Advances in Medical Oncology
|
January 8, 2021
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial
Natalie Reizine, Everett E Vokes, Ping Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided Dosing
Smita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.
Plos One
|
March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One
|
July 2, 2014
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue
Daniel V T Catenacci, Wei-Li Liao, Sheeno Thyparambil, et al.
Plos One
|
October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One
|
December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
JCO Precision Oncology
|
December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2019
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Steven B Maron, Leah M Chase, Samantha Lomnicki, et al.
Cancer Discovery
|
February 17, 2018
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i>-Amplified Gastroesophageal Adenocarcinoma
Steven B Maron, Lindsay Alpert, Heewon A Kwak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
David S Hong, Patricia LoRusso, Omid Hamid, et al.
Therapeutic Advances in Medical Oncology
|
January 8, 2021
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial
Natalie Reizine, Everett E Vokes, Ping Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided Dosing
Smita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.
Plos One
|
March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One
|
July 2, 2014
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue
Daniel V T Catenacci, Wei-Li Liao, Sheeno Thyparambil, et al.
Plos One
|
October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One
|
December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
JCO Precision Oncology
|
December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
Page
of 7